Comment from The Alliance for mRNA Medicines

Summary: The Alliance for mRNA Medicines (AMM) supports the FDA's Plausible Mechanism Framework but urges the agency to provide greater clarity on its scope, manufacturing requirements, and clinical data expectations for very rare diseases. They specifically advocate for a more flexible, platform-based regulatory approach that accounts for the unique lifecycle and logistical challenges of individualized therapies.